174 related articles for article (PubMed ID: 24332273)
1. Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: clinical and laboratory evaluation.
Gil S; Leal RO; McGahie D; Sepúlveda N; Duarte A; Niza MM; Tavares L
Res Vet Sci; 2014 Feb; 96(1):79-85. PubMed ID: 24332273
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega.
Leal RO; Gil S; Duarte A; McGahie D; Sepúlveda N; Niza MM; Tavares L
Res Vet Sci; 2015 Apr; 99():87-95. PubMed ID: 25747956
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats.
de Mari K; Maynard L; Sanquer A; Lebreux B; Eun HM
J Vet Intern Med; 2004; 18(4):477-82. PubMed ID: 15320583
[TBL] [Abstract][Full Text] [Related]
4. Limited efficacy of topical recombinant feline interferon-omega for treatment of cats with acute upper respiratory viral disease.
Ballin AC; Schulz B; Helps C; Sauter-Louis C; Mueller RS; Hartmann K
Vet J; 2014 Dec; 202(3):466-70. PubMed ID: 25457261
[TBL] [Abstract][Full Text] [Related]
5. Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline IFN-gamma.
Tanabe T; Yamamoto JK
J Interferon Cytokine Res; 2001 Dec; 21(12):1039-46. PubMed ID: 11798461
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy of the subcutaneous low recombinant feline interferon-omega administration protocol for feline chronic gingivitis-stomatitis in feline calicivirus-positive cats.
Matsumoto H; Teshima T; Iizuka Y; Sakusabe A; Takahashi D; Amimoto A; Koyama H
Res Vet Sci; 2018 Dec; 121():53-58. PubMed ID: 30359811
[TBL] [Abstract][Full Text] [Related]
7. Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega.
Litzlbauer P; Weber K; Mueller RS
Cytokine; 2014 Mar; 66(1):54-9. PubMed ID: 24548425
[TBL] [Abstract][Full Text] [Related]
8. The Use of Recombinant Feline Interferon Omega Therapy as an Immune-Modulator in Cats Naturally Infected with Feline Immunodeficiency Virus: New Perspectives.
Leal RO; Gil S
Vet Sci; 2016 Oct; 3(4):. PubMed ID: 29056740
[TBL] [Abstract][Full Text] [Related]
9. Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter.
Gil S; Leal RO; Duarte A; McGahie D; Sepúlveda N; Siborro I; Cravo J; Cartaxeiro C; Tavares LM
Res Vet Sci; 2013 Jun; 94(3):753-63. PubMed ID: 23122808
[TBL] [Abstract][Full Text] [Related]
10. Use of recombinant interferon omega in feline retrovirosis: from theory to practice.
Doménech A; Miró G; Collado VM; Ballesteros N; Sanjosé L; Escolar E; Martin S; Gomez-Lucia E
Vet Immunol Immunopathol; 2011 Oct; 143(3-4):301-6. PubMed ID: 21719116
[TBL] [Abstract][Full Text] [Related]
11. 16alpha-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression.
Pedersen NC; North TW; Rigg R; Reading C; Higgins J; Leutenegger C; Henderson GL
Vet Immunol Immunopathol; 2003 Aug; 94(3-4):133-48. PubMed ID: 12909410
[TBL] [Abstract][Full Text] [Related]
12. Follow-Up of Viral Parameters in FeLV- or FIV-Naturally Infected Cats Treated Orally with Low Doses of Human Interferon Alpha.
Gomez-Lucia E; Collado VM; Miró G; Martín S; Benítez L; Doménech A
Viruses; 2019 Sep; 11(9):. PubMed ID: 31514435
[TBL] [Abstract][Full Text] [Related]
13. Association between feline immunodeficiency virus (FIV) plasma viral RNA load, concentration of acute phase proteins and disease severity.
Kann RK; Seddon JM; Kyaw-Tanner MT; Henning J; Meers J
Vet J; 2014 Aug; 201(2):181-3. PubMed ID: 24703323
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega.
Hampel V; Schwarz B; Kempf C; Köstlin R; Schillinger U; Küchenhoff H; Fenske N; Brill T; Hirschberger J
J Vet Intern Med; 2007; 21(6):1340-6. PubMed ID: 18196745
[TBL] [Abstract][Full Text] [Related]
15. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis?
Arai M; Earl DD; Yamamoto JK
Vet Immunol Immunopathol; 2002 Mar; 85(3-4):189-204. PubMed ID: 11943320
[TBL] [Abstract][Full Text] [Related]
16. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
17. Reduced provirus burden and enhanced humoral immune function in AZT-treated SCID-feline mice inoculated with feline immunodeficiency virus.
Johnson CM; Selleseth DW; Ellis MN; Childers TA; Tompkins MB; Tompkins WA
Vet Immunol Immunopathol; 1995 May; 46(1-2):169-80. PubMed ID: 7618256
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment with feline interferon omega and the course of subsequent infection with feline herpesvirus in cats.
Haid C; Kaps S; Gönczi E; Hässig M; Metzler A; Spiess BM; Richter M
Vet Ophthalmol; 2007; 10(5):278-84. PubMed ID: 17760705
[TBL] [Abstract][Full Text] [Related]
20. Activity of feline interferon-omega after ocular or oral administration in cats as indicated by Mx protein expression in conjunctival and white blood cells.
Bracklein T; Theise S; Metzler A; Spiess BM; Richter M
Am J Vet Res; 2006 Jun; 67(6):1025-32. PubMed ID: 16740097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
